History of assay achievements
A major research focus within the Radboud University Medical Centre is on immune-regulation and immunotherapy.
For monitoring of KLH-containing cancer vaccines we recently developed the first quantitative-assay to detect human anti-KLH antibodies in serum/plasma (Aarntzen et al. CII 2012).
In recently published articles we describe our ELISA method and diverse applications of anti-KLH analysis in clinical trials:
Simultaneous presence of non- and highly mutated KLH-specific plasmablasts early after primary KLH immunization
Monitoring of dynamica changes in KLH-specific B cells in KLH-vaccinated cancer patients
Intranodal vaccinations with mRNA-optimized dendritic cells in metastatic melanoms patients
Targeting CD4+ T helper cells improves the induction of anti-tumor responses in dendrtitic cell based vaccination
Giesecke et al. JI 2018
Wimmers et al. Sci Rep 2017
Bol et al. Oncoimm. 2015
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-baed vaccination in metastatic melanoma
Vaccination with mRNA-eclectroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients
Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccine parameters.
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxythymedine PET imaging
Route of administation modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients